bmn-673 has been researched along with Thrombocytopenia* in 1 studies
1 trial(s) available for bmn-673 and Thrombocytopenia
Article | Year |
---|---|
Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials.
Poly(ADP-ribose) polymerase inhibitors, such as talazoparib, may affect hematopoiesis. This analysis characterized the relationship between talazoparib exposure and the most common grade ≥ 3 hematopoietic adverse events (AEs) leading to dose modification in the phase 2 (ABRAZO) and phase 3 (EMBRACA) trials. The relationship between time-varying average talazoparib concentration (C Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Dosage Calculations; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Middle Aged; Mutation; Neutropenia; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Proportional Hazards Models; Thrombocytopenia | 2020 |